REXAHN Pharmaceuticals Reviews

Recommend to a friend
Approve of CEO
REXAHN Pharmaceuticals Chairman and CEO Chang H. Ahn
Chang H. Ahn
0 Ratings

REXAHN Pharmaceuticals Awards & Accolades

Let us know if we're missing any workplace or industry recognition – Add an award

Additional Info

Unlock Profile
Headquarters Rockville, MD
Size 1 to 50 Employees
Founded Unknown
Type Company - Public (RNN)
Industry Biotech & Pharmaceuticals
Revenue $1 to $5 million (USD) per year
Competitors Pfizer, GlaxoSmithKline, Roche

Rexahn Pharmaceuticals has its R&D sights set on difficult-to-treat cancers and central nervous system (CNS) disorders. A biopharmaceutical company, Rexahn has three drug candidates in clinical stages of development, including its lead candidate and pancreatic cancer treatment Archexin (designed to inhibit a protein involved in cancer cell proliferation); Serdaxin, a depression and Parkinson's disease drug; and Zoraxel, a treatment for erectile dysfunction. The company also has seven cancer drugs in preclinical development. It develops its candidates through its ... More

Work at REXAHN Pharmaceuticals? Share Your Experiences

REXAHN Pharmaceuticals

Click to Rate